Home > Pressrelease > Atrial Fibrillation Drugs Market size to exceed $17Bn by 2025

Atrial Fibrillation Drugs Market size to exceed $17Bn by 2025

  • Published Date: April 26, 2019

Atrial Fibrillation Drugs Market size is set to exceed USD 17.0 billion by 2025; according to a new research study published by Global Market Insights Inc.

Increasing rate of geriatric population across the world is one of the major growth augmenting factors, since people above the age of 65 years are more prone to chronic diseases such as atrial fibrillation, diabetes, hypertension, etc. Additionally, rising prevalence of cardiovascular diseases, especially in the U.S. will further boost the growth of atrial fibrillation drugs market in the forthcoming years.

Side effects associated with the regular intake of atrial fibrillation drugs is one of the major growth impending factors. Side effects such as excessive bleeding, tiredness, etc. will hamper market growth. Moreover, lack of awareness among people about the latest pharmaceutical therapies is another growth hindering factor.

Atrial Fibrillation Drugs Market

Get more details on this report - Request Free Sample PDF

Browse key industry insights spread across 350 pages with 693 market data tables & 35 figures & charts from the report, “Atrial Fibrillation Drugs Market Size By Product (Antiarrhythmic Drugs, Anticoagulant Drugs {Vitamin K Antagonists, Novel Oral Anticoagulants [Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors]}), By AF Condition (Paroxysmal, Persistent, Permanent), By Application (Heart Rhythm Control, Heart Rate Control) By Route of Administration (Oral, Injectable) By End-use (Hospitals, Cardiac Centers, Ambulatory Surgical Centers) Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025” in detail along with the table of contents:

Anticoagulants segment of atrial fibrillation drugs market was valued at around USD 11,554.6 million in the year 2018. Anticoagulants were introduced with an aim to reduce the rate of stroke in individuals suffering from atrial fibrillation. Patients with atrial fibrillation should be considered for antiplatelet or anticoagulation therapy based on patient's age and presence of other risk factors. A significant rise in the incidence of atrial fibrillation associated strokes over the recent years have increased the demand of anticoagulants thus, augmenting atrial fibrillation market growth.

Use of atrial fibrillation drugs for paroxysmal condition will grow at 2.9% over the estimation period. The paroxysmal atrial fibrillation occurs when there are irregular electric pathways in the heart and the heart is not pumping enough oxygen-rich blood, that leads to erratic heart rates that can last for upto 24 hours. The occurrence of paroxysmal atrial fibrillation is evidently increasing among the geriatric population as well as in young generation owing to rise in factors such as valvular disfunctions, coronary artery disease, previous heart surgery etc. Hence, the above mentioned reasons will augment the growth of atrial fibrillation drugs market.

Application of atrial fibrillation drugs market in heart rhythm control was valued at USD 3,312.4 million in the year 2018. Heart rhythm control is the maintenance and acute restoration of sinus rhythm in patients suffering from atrial fibrillation. The achievement of heart rhythm control can indeed reduce atrial fibrillation-associated mortality and morbidity. Patients that have coexistent cardiovascular diseases such as obstructive sleep apnea, hypertension, valvular heart disease and heart failure have a much higher increased risk for progression of arrhythmia. Hence, the increasing incidence of such cardiovascular diseases coupled with geriatric population will augment heart rhythm control segment growth.

Oral atrial fibrillation drug administration market will grow at 3.1% over the forecast period. The aim of medical therapy for patients suffering from atrial fibrillation are to avoid the risk of complications, sustain sinus rhythm and minimize atrial fibrillation symptoms. Oral drug therapies such as warfarin denotes the cornerstone of anticoagulant oral therapy for patients at high risk of thromboembolic events. With increase in incidence of atrial strokes across the world, oral drug therapies are experiencing an upward trajectory of atrial fibrillation dugs market growth.

The use of atrial fibrillation drugs in hospitals is estimated to grow at 3% over the forecast period. Rising popularity of anticoagulant and antiarrhythmic drugs in developed and developing countries will strongly contribute to larger demand for atrial fibrillation drugs in hospitals. Moreover, increasing investments and partnerships with various manufacturing firms will further augment the atrial fibrillation drugs market growth.

The U.S. atrial fibrillation drugs market is the largest in the world and projected to expand at a CAGR of 2.4% over the forecast period. During the forecast timeframe, it will continue to grow with stable growth and lead the industry at a global level. Increasing geriatric population, rising venture capital investments by manufacturing firms, growing adoption rate of new pharmaceutical drugs to address severe conditions of patients suffering from atrial fibrillation in the country should drive the U.S. atrial fibrillation drugs market during the projection years.

Some of the key industry players operating in the global atrial fibrillation market are Johnson & Johnson, Pfizer, Sanofi S.A, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Co., Daiichi Sankyo Company, Limited and AstraZeneca. The industry participants emphasize on acquisitions and mergers, geographical expansion and novel product developments to strengthen their position in the market and gain competitive advantage over its peers.   

Atrial fibrillation drugs market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2014 to 2025, for the following segments:

Atrial Fibrillation Drugs Market by Product

  • Antiarrhythmic Drugs
  • Anticoagulant Drugs
    • Vitamin K Antagonists
    • Novel Oral Anticoagulants (NOACS)
      • Direct Thrombin Inhibitors
      • Direct Factor Xa Inhibitors

Atrial Fibrillation Drugs Market by Atrial Fibrillation Type

  • Paroxysmal
  • Persistent
  • Permanent

Atrial Fibrillation Drugs Market by Application

  • Heart Rhythm Control
  • Heart Rate Control

Atrial Fibrillation Drugs Market by Route of Administration

  • Oral
  • Injectable

Atrial Fibrillation Drugs Market by End-use

  • Hospitals
  • Cardiac Centers
  • Ambulatory Surgical Centers
  • Others

The above information is provided for the following regions/countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Russia
    • Poland
    • Switzerland
    • Belgium
    • Czech Republic
    • Netherlands
    • Sweden
    • Hungary
    • Austria
    • Portugal
    • Denmark
    • Norway
    • Finland
    • Ireland
    • Turkey
    • Greece
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Taiwan
    • New Zealand
    • Singapore
  • Latin America
    • Brazil
    • Argentina
    • Venezuela
    • Columbia
    • Mexico
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt


Authors: Sumant Ugalmugle, Rupali Swain